What Should My Estradiol Level Be on HRT?

Most clinical guidelines set the target serum estradiol level during hormone replacement therapy at roughly 100 to 200 pg/mL, a range modeled on the levels found in premenopausal women during a normal menstrual cycle. But that single number hides a lot of nuance. Your ideal level depends on why you’re taking HRT, how you’re taking it, what your body does with the estradiol once it’s absorbed, and even which lab method was used to measure it.

Where the 100 to 200 pg/mL Target Comes From

The 100 to 200 pg/mL range is the most widely cited target across both menopausal and gender-affirming hormone therapy. For transgender women and transfeminine individuals, current consensus guidelines specifically recommend serum estradiol concentrations within this window when using oral, subcutaneous, or transdermal estradiol, with or without an antiandrogen.¹ The logic behind the number is straightforward: these targets are based on premenopausal female reference ranges, essentially mimicking the estradiol levels a healthy ovary would produce during the follicular or luteal phase of a menstrual cycle.²

For postmenopausal women taking HRT to manage symptoms like hot flashes or to protect bone density, the same ballpark applies, though clinicians sometimes accept slightly lower levels depending on the goal. The 100 to 200 pg/mL figure is a clinical consensus, not a hard biological threshold. Some people feel great and achieve their clinical goals at 80 pg/mL. Others genuinely need levels closer to 200 pg/mL to suppress symptoms or, in the case of feminizing therapy, to adequately lower testosterone.

Why the Route You Take Estradiol Matters

One of the biggest factors determining your actual blood level is how the estradiol enters your body. The three main routes are oral (pills), transdermal (patches, gels, or creams), and injectable (intramuscular or subcutaneous shots). Each one produces a different pharmacokinetic profile, and the differences are not trivial.

When you swallow an estradiol pill, it passes through the gut and liver before reaching the rest of your bloodstream. This “first-pass” metabolism chews up a large fraction of the dose. Oral estrogens have minimal systemic bioavailability, in the range of only 2% to 10%, because so much is metabolized on that first pass through the liver.³ A major consequence is that oral estradiol produces relatively high levels of estrone (a weaker estrogen metabolite) compared to estradiol itself. By contrast, transdermal and injectable routes bypass the liver initially, so a larger share of what you absorb circulates as actual estradiol rather than estrone.

This distinction matters when interpreting your lab results. If you’re on oral estradiol and your serum estradiol reading is, say, 70 pg/mL, you may still have a large pool of circulating estrone doing some of the estrogenic heavy lifting. Someone on a patch with the same 70 pg/mL estradiol reading has less estrone in the mix. The standard 100 to 200 pg/mL target was developed largely around oral regimens, so applying it rigidly to transdermal users can be misleading. Many clinicians treating transdermal patients focus more on symptom resolution than on hitting an exact number.

Injectable Estradiol and Peaks and Troughs

Injections of estradiol valerate or estradiol cypionate add another layer of complexity because your levels swing between a peak (usually one to three days after the injection) and a trough (right before your next dose). A single blood draw only captures one point on that curve. If your blood was drawn the day after your shot, you might see 300 or 400 pg/mL. If drawn on the day before your next injection, you might see 80 pg/mL. Both readings came from the same person on the same dose.

Current guidelines suggest intramuscular dosages ranging from 2 to 10 mg weekly or 5 to 30 mg every two weeks, using estradiol cypionate or valerate. However, a review of injectable dosing in gender-affirming therapy found that starting at 5 mg weekly or lower is advisable to avoid pushing estradiol levels well above the physiologic range.⁴ Supraphysiologic levels, which loosely means levels persistently above 200 to 300 pg/mL, are not necessarily more effective and may carry additional risks.

Most clinicians who prescribe injectable estradiol recommend drawing your trough level, the reading taken at the lowest point in the cycle, just before your next injection. This gives the most conservative estimate of whether your baseline level is adequate. If your trough sits around 100 pg/mL or above, the general consensus is that you’re well within the therapeutic window for most clinical goals.

Testosterone Suppression in Feminizing Therapy

For transfeminine individuals, one of the primary goals of estradiol is suppressing testosterone production. Many people take an antiandrogen like spironolactone or cyproterone acetate alongside estradiol, but some pursue estrogen monotherapy, relying on estradiol alone to do the job. The question then becomes: how high does your estradiol need to be to keep testosterone in the female range?

A study of transfeminine patients on estrogen monotherapy found that testosterone suppression was achieved in every patient whose serum estradiol was above 100 pg/mL.⁵ That’s a small study, and “every patient” in a sample of seven is not the same as a guarantee for everyone. Still, it lines up with broader clinical observations that estradiol levels consistently above 100 pg/mL tend to suppress gonadal testosterone production effectively. Below that threshold, testosterone suppression becomes less reliable without adding an antiandrogen.

This is one situation where the lower end of the 100 to 200 pg/mL range really does seem to matter. If you’re trying to suppress testosterone without an antiandrogen and your trough is sitting at 60 pg/mL, you may not be getting the full feminizing benefit you’re after.

The Bone Health Threshold Is Lower Than You Might Think

Estradiol plays a central role in maintaining bone density regardless of sex. One of the well-established benefits of HRT in postmenopausal women is reduced bone loss, and the estradiol levels needed to achieve this are actually quite modest. A study of postmenopausal women on estrogen replacement found that circulating estradiol levels between 60 and 90 pg/mL significantly reduced markers of bone resorption compared to lower levels. Pushing estradiol higher than 90 pg/mL did not provide additional bone-protective benefit. The researchers concluded that a minimum of 60 pg/mL is the threshold needed to prevent postmenopausal bone loss.⁶

Transdermal estrogen delivery at relatively low doses has also been shown to meaningfully increase total bone mineral density in postmenopausal women, with even doses as low as 0.25 mg per day for three years producing significant improvement.⁷ Separately, research on elderly women found that those with very low baseline estradiol, under about 9 pg/mL, were the best candidates for estrogen therapy aimed at osteoporosis prevention, because they had the most to gain.⁸

The takeaway for bone protection: you don’t need to be at the top of the 100 to 200 pg/mL range. Levels in the 60 to 90 pg/mL zone already do the job. If you’re taking HRT primarily for skeletal health, chasing higher numbers with bigger doses isn’t doing your bones any extra favors and may carry risks that aren’t worth it.

Blood Clot Risk Depends on How You Take It

One of the most commonly cited risks of HRT is venous thromboembolism, or blood clots forming in deep veins, sometimes traveling to the lungs. This risk is real, but it is strongly tied to oral estrogen specifically. Estradiol taken by mouth passes through the liver on every cycle, and that hepatic exposure increases the production of clotting factors.

The data on this point is fairly clear. Oral HRT tablets are associated with blood clot risk, while patches, creams, and gels are not.⁹ A large population-based study directly compared transdermal estradiol patch users to oral estrogen-only users and found that the transdermal group had a significantly lower rate of blood clots even after adjusting for other risk factors.¹⁰

This doesn’t mean oral estradiol is dangerous for everyone. The absolute risk of blood clots on oral HRT remains low in most people. But if you have additional risk factors for clots, like a family history, obesity, smoking, or a known clotting disorder, the transdermal route is generally considered safer. Your target estradiol level stays the same regardless of the route; it’s the way the drug gets into your bloodstream that changes the clot risk profile, not the number on the lab report.

How Body Weight Affects Your Levels

Fat tissue contains an enzyme called aromatase that converts androgens into estrogen. This means your body composition can influence how much estradiol you end up with in your blood after taking a given dose. Research in postmenopausal women found that serum estradiol levels after daily HRT were significantly correlated with body mass index: women with higher BMI tended to achieve higher estradiol levels on the same dose.¹¹

This has practical implications for dosing. If you’re in a larger body, a standard starting dose might push your estradiol higher than expected. Conversely, if you’re very lean, you may need a slightly higher dose to reach the same target. Your clinician should be checking levels and adjusting rather than assuming one dose fits all, but it’s worth being aware that body composition is part of why two people on the same prescription can have wildly different lab results.

Your Lab Results May Not Mean What You Think

Not all estradiol tests are created equal, and this is an underappreciated source of confusion. The two main lab methods are immunoassays (the cheaper, more common type) and liquid chromatography-tandem mass spectrometry, often abbreviated LC-MS/MS (the more expensive and precise method).

The two methods generally agree at higher estradiol concentrations, but can diverge at lower levels. One evaluation found that immunoassay results correlated well with LC-MS/MS overall, but the immunoassay readings carried a negative bias of roughly 18 pg/mL compared to the mass spectrometry results.¹² That kind of discrepancy might not matter much when your level is 150 pg/mL, but it could be significant if you’re hovering around 60 to 80 pg/mL and trying to determine whether you’ve cleared a clinically meaningful threshold.

Beyond the raw accuracy question, the measurement method can also change what appears to be associated with your estradiol level. A study comparing the two approaches in men found that immunoassay-measured estradiol showed a significant positive association with C-reactive protein (a marker of inflammation) and a significant inverse association with ankle-brachial index (a vascular health marker). When the same samples were measured by mass spectrometry, neither association held up.¹³ In other words, the immunoassay was picking up something other than just estradiol, likely cross-reacting with other compounds, and creating phantom associations that disappeared under more precise measurement.

The practical lesson: if your lab results seem oddly low or high and don’t match how you feel, ask which assay was used. If you’re being monitored at lower estradiol levels, especially below 60 pg/mL, mass spectrometry is more reliable. Many standard hospital and commercial labs default to immunoassay, and a result of 50 pg/mL on an immunoassay might reflect a true level somewhere in the 50 to 70 range depending on what else is in your blood.

Why Some People Feel Great at 80 and Others Still Struggle at 180

One of the most frustrating aspects of HRT is the enormous person-to-person variability in how estradiol actually works at the tissue level. Your serum level is just the concentration of hormone floating in your blood. What matters functionally is how your cells respond to it, and that varies enormously.

Research on human breast tissue explants found that estrogen receptor expression varied by more than 80-fold between individual donors. Even more strikingly, the level of receptor expression didn’t predict how strongly the tissue actually responded to estradiol treatment. Some donors with relatively few receptors showed a robust functional response, while others with abundant receptors showed a muted one.¹⁴ Receptor quantity, in other words, isn’t the bottleneck. Downstream signaling, co-factors, and other variables that aren’t captured by any standard lab test all influence how your body actually uses the estradiol in your blood.

This is the main reason experienced clinicians treat the patient, not the number. A serum estradiol of 120 pg/mL that resolves your hot flashes, maintains your bone density, and leaves you feeling well is a better result than a “perfect” 175 pg/mL that was achieved by pushing to a higher dose that gives you migraines or breast tenderness. The target range is a guide for getting in the right neighborhood, not a prescription for a specific number.

Hot Flashes, Symptom Relief, and What Levels Actually Predict

If you’re taking HRT for menopausal symptoms, you might assume there’s a tidy threshold: get your estradiol above X and the hot flashes stop. Reality is messier. A study of midlife women found that it wasn’t just the absolute estradiol level that predicted hot flash frequency, but also the variability in hormone levels over time. Higher peak estradiol values were associated with fewer and less severe hot flashes, but progesterone variability was actually a stronger predictor than estradiol alone. Greater fluctuation in progesterone correlated with reduced hot flash frequency and severity.¹⁵

The implication is that menopausal symptom control isn’t purely an estradiol story. Progesterone (which many people on HRT take alongside estradiol for uterine protection) plays its own role. And the stability of your levels, avoiding dramatic swings, may matter as much as the absolute number. This is another reason injectable estradiol users sometimes struggle more with symptom breakthrough near the end of their dosing cycle: the trough may drop low enough to trigger vasomotor symptoms even if the average level across the cycle looks fine on paper.

Lipids and Cardiovascular Markers

Estradiol’s effects extend well beyond the symptoms you can feel. HRT has measurable impacts on cardiovascular biomarkers, including blood lipids. A study comparing HRT to placebo found that treatment significantly reduced several atherogenic markers, including total cholesterol, LDL cholesterol, and lipoprotein(a). The reduction in lipoprotein(a) was inversely correlated with the change in estradiol, meaning the more estradiol levels rose, the more lipoprotein(a) dropped.¹⁶ These shifts were detectable within three months of starting therapy.

The cardiovascular picture is far from simple, though, and this is not a reason to push for higher estradiol levels. The favorable lipid changes have to be weighed against the clotting risks discussed earlier, and timing of HRT initiation relative to menopause onset appears to matter for overall cardiovascular outcomes. What the lipid data does suggest is that HRT at standard doses and target levels is doing something metabolically meaningful beyond symptom relief, which is worth discussing with your provider if cardiovascular risk is part of your health picture.

When to Recheck and What to Ask For

Timing your blood draw correctly makes a big difference in how useful the result is. For oral estradiol, most clinicians recommend drawing blood in the morning, roughly 12 to 24 hours after your last dose, to capture a relatively stable trough. For patches, levels are more stable throughout the day, so timing matters less, though drawing toward the end of a patch-wear cycle gives the most conservative reading. For injections, draw your blood on the day of or the day before your next shot to capture the trough.

If you’re newly starting HRT or adjusting your dose, expect your clinician to recheck levels after about four to six weeks, which gives the body time to reach a steady state. Once your levels are stable and your symptoms are well-managed, annual or semiannual checks are typical. If you’re switching routes, say from pills to patches, don’t assume your dose will translate directly. The different bioavailability profiles mean the same “dose” on paper can produce very different blood levels.

When reviewing results with your provider, two questions are worth asking that patients often skip. First, which assay did the lab use? If you’re on a low dose or targeting the lower end of the range, the answer matters. Second, what was your estrone level? Estrone is rarely ordered by default, but it can provide a fuller picture, especially for oral estradiol users whose estrone-to-estradiol ratio may be high. A low estradiol reading paired with an elevated estrone might indicate that you’re absorbing the medication fine but converting most of it during first-pass metabolism, which could be a reason to consider a non-oral route rather than simply increasing the dose.